Follow us on Twitter
This page is updated frequently with new Roti-related patent applications. Subscribe to the Roti RSS feed to automatically get the update: related Roti RSS feeds. RSS updates for this page: Roti RSS
|| List of recent Roti-related patents
| Tomato spotted wilt virus and/or impatiens necrotic spot virus resistance in cultivated lettuce|
The invention relates to a lettuce plant (lactuca sativa l.), which may comprise a genetic determinant, which confers resistance to tomato spotted wilt virus (tswv) and/or impatiens necrotic spot virus (insv), and which is as found in plants grown from seeds of which a representative sample was deposited under ncimb accession number ncimb 42023. The invention further provides seeds, progeny, propagation material and food products from the plant..
| Carotid sheath with entry and tracking rapid exchange dilators and method of use|
Dilators and sheaths for use in minimally invasive vascular therapy are disclosed. In some embodiments, the dilators include a slot that accesses a guidewire lumen within the dilator.
| Methods and uses of cytochrome p450 inhibitors|
Methods are provided for treating or preventing chronic obstructive pulmonary diseases such as emphysema, and fibrotic diseases including heart, liver, kidney and vascular diseases, by administering to a subject a pharmaceutical composition comprising a compound that inhibits cytochrome p450ra or cyp26.. .
| Methods and devices for affecting nerve function|
Various methods and devices are described for affecting nerve function in the carotid body, renal nerves, and other nerves. Syringes, endovascular catheters, drug-eluting balloons, drug-eluting stents, and agent delivery patches are used to deliver a neuromodulatory agent to one or more nerves in order to treat a disease state..
| Nanoparticle-based delivery system with oxidized phospholipids as targeting ligands for the prevention, diagnosis and treatment of atherosclerosis|
Disclosed are nanoparticle-based medicine/nutrient delivery system that are coated or incorporated with oxidized phospholipids as targeting ligands. Such delivery systems can specifically target macrophages, which are determinant cells in the aortic wall for atherosclerotic lesion development, to significantly increase bioavailability and specificity for the prevention, diagnosis and treatment of atherosclerosis..
|Compositions and methods for transdermal delivery of tertiary amine drugs|
Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a rate-controlling membrane and a skin-contacting face adhesive apart from the polymer matrix..
|Ultrasound diagnostic device and method for controlling ultrasound diagnostic device|
An ultrasound diagnostic device to which an ultrasound probe is connectable, measuring an imt of a vascular wall in a carotid artery, includes: a transmission-reception processing unit supplying a transmission signal causing the ultrasound probe to transmit an ultrasound to short-axis cross-sections along the carotid artery, and receiving a signal based on a reflected ultrasound and generating a reception signal for frames at each position; a two-dimensional image generation unit generating two-dimensional images corresponding to the frames; a bulb boundary detection unit measuring a perimeter or area of the vascular wall in each image, and detecting a boundary between a cca and a cca bulb from the perimeter or area; and position information indicating a position where each image is acquired; a roi determination unit determining a roi defining an imt measurement range with respect to the boundary; and an imt measurement unit measuring the imt within the images.. .
|Cysteamine in the treatment of fibrotic disease|
Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ecm) deposition, interstitial fibroblasts, interstitial volume, expression of collagen i mrna and protein, expression of profibrotic cytokines and macrophage infiltration by cysteamine treatment..
|Pyridazine derivatives useful in therapy|
The invention provides compounds of formula i, (i) wherein: r represents a cyclic group selected from phenyl, heteroaryl, heterocyclyl and c 3-6 cycloalkyl; 10 wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo, c -6 alkyl optionally substituted with 1-3 halogen atoms, phenyl, c -6 alkoxy optionally substituted with 1-3 halogen atoms, cyano, heteroaryl 1a and heterocyclyl 1a; and wherein each cyclic group is optionally fused to a benzene ring or a 5- or 16-membered heteroaromatic or heterocyclic ring each containing from 1 to 3 heteroatoms (selected from n, o and s); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl and heterocyclyl 1a may additionally be substituted with ═o; 20 x represents a bond or c -6 alkylene (which may be straight or branched); r 2 represents h or c -6 alkyl; r 3 represents h or c -6 alkyl; y represents a bond or c -6 alkylene (which may be straight or branched, and optionally substituted with oh or cf 3); 2 r 4 represents a cyclic group selected from phenyl, heteroaryl 4, heterocyclyl 4 and c 3-6 cycloalkyl; wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo, c -6 alkyl optionally substituted with 1-3 halogen atoms, tet01063wo 4 phenyl, c -6 alkyl substituted with phenyl, c -6 alkoxy optionally substituted with -3 halogen atoms, cyano, heteroaryl 4a and heterocyclyl 4a; and wherein each cyclic group is optionally fused to benzene ring or a 5- or 6-membered heteroaromatic or heterocyclic ring each containing from 1 to 3 heteroatoms (selected from n, o and s); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl 4 and heterocyclyl 4a may additionally be substituted with ═o; heteroaryl, heteroaryl 1a, heteroaryl 4 and heteroaryl 4a independently represent a 5- or 6-membered heteroaryl group containing from 1 to 3 heteroatoms (selected from n, o and 10 s); and heterocyclyl, heterocyclyl 1a, heterocyclyl 4 and heterocyclyl 4a independently represent a 5- or 6-membered heterocyclyl group containing from 1 to 3 heteroatoms (selected from n, o and s); and pharmaceutically acceptable salts and solvates thereof.1 the compounds are useful as pharmaceuticals, particularly in the treatment of fibrotic diseases, cancer and pain.. .
|Il-33 antagonists and uses thereof|
The present invention provides interleukin-33 (il-33) antagonists comprising one or more il-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the il-33-binding domains can comprise an il-33-binding portion of an st2 protein and/or an extracellular portion of an il-1 racp protein.
|Embolectomy catheters and methods for treating stroke and other small vessel thromboembolic disorders|
Embolectomy catheters, rapid exchange microcatheters, systems and methods for removing clots or other obstructive matter (e.g., thrombus, thromboemboli, embolic fragments of atherosclerotic plaque, foreign objects, etc.) from blood vessels. This invention is particularly useable for percutaneous removal of thromboemboli or other obstructive matter from small blood vessels of the brain, during an evolving stroke or period of cerebral ischemia.
|Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression|
The present invention relates to methods of using a g protein-coupled receptor (gpcr) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the gpcr couples to gi.
|Embolic protection device|
Embolic protection devices useful for filtering emboli during interventional cardiac, vascular, or other procedures are described. The device can include first and second expandable mesh filters having open and closed ends.
|Ultrasound diagnostic device and ultrasound diagnostic device control method|
An ultrasound diagnostic device to which an ultrasound probe is connectable, measuring an imt of a vascular wall in a carotid artery, including: a transmission unit supplying a transmission signal to the probe for causing ultrasound transmission along a longitudinal cross-section of the carotid artery; a reception unit receiving a signal based on a reflected ultrasound received by the probe, and generating a reception signal; a vascular feature calculation unit extracting position information from the reception signal, including at least one of: piece positions for vascular wall pieces; and a relative relationship between piece positions, and detecting a boundary between a cca and a cca bulb according to variation in the position information with respect to the longitudinal direction of the carotid artery; a roi determination unit determining a roi defining an imt measurement range with respect to the boundary; and an imt measurement unit measuring the imt.. .
|Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child|
Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component..
|Endovascular catheters for trans-superficial temporal artery transmural carotid body modulation|
Methods, devices, and systems for carotid body modulation via accessing a target site with an endovascular approach through a superficial temporal artery.. .
|Pharmaceutical composition comprising rotigotine salts (acid or na), especially for iontophoresis|
The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol (rotigotine), their use as a medicament, for example for the treatment of cns disorders like parkinson disease, rls, fibromyalgia and/or depression, in particular through electromotive administration. The present invention relates to pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of rotigotine to at least one target tissue.
|Methods for preventing or treating necrotizing enterocolitis|
The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis.
|Ink set for ink jet recording, and recording apparatus|
An ink set includes a recording ink and a displacement ink. The recording ink contains a pigment, a resin, water, and a first surfactant and is substantially free of alkyl polyols with a normal boiling point of 280° c.
|Novel antithrombotic and antiatherosclerotic agent and method for producing same (variants)|
The use of 2-[2-cyano-2-[5-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-ylidene]ethylidene]indolin-3-one of formula i is proposed as a biologically active compound exhibiting the properties of exogenous nitric oxide donor, a platelet aggregation inhibitor, also exhibiting antihypertensive activity and activating activity towards the soluble guanylate cyclase enzyme. Variants of methods for synthesizing the above compound are also proposed..
|Dissolution of arterial plaque|
Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations.
|Feed additive composition|
A feed additive composition comprising a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. Nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (fcr) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g.
|Alpha helix mimetic compositions for treating cancer and other cbp/catenin-mediated diseases and conditions|
Alpha-helix mimetic structures and compounds represented by the formula (i) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed..
|Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists|
The present invention provides 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior..
|Methods for rapidly treating severe hypoglycemia|
Disclosed is a method for treating or preventing hypoglycemia in a patient comprising administering an effective amount of a composition comprising a glucagon peptide which has been dried in a non-volatile buffer, and wherein the glucagon peptide has a ph memory that is about equal to the ph of the glucagon peptide in the non-volatile buffer, and an aprotic polar solvent, wherein the moisture content of the formulation is less than 5%, and wherein the dried glucagon peptide maintains the ph memory that is about equal to the ph of the glucagon peptide in the non-volatile buffer when the dried glucagon peptide is reconstituted in the aprotic polar solvent, wherein the patient has been diagnosed as having a blood glucose level between 0 mg/dl and less than 50 mg/dl or has an indication of impending hypoglycemia based on a blood glucose monitoring device before administration of the composition, and wherein the patient has a blood glucose level greater than 50 mg/dl to 180 mg/dl within 1 to 20 minutes after administration of the composition.. .
|System and method for delivering protease inhibitors|
The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“ta”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation.
|Metal sensitive mutants of matrix metalloproteases and uses thereof|
Provided herein are methods of using modified matrix metalloprotease (mmp) enzymes that exhibit regulated activity in the presence of calcium. The methods include conditionally controlling the activity of the mmps through the use of calcium to treat fibrotic diseases or conditions involving a component of the extracellular matrix (ecm)..
|Plaque array methods and compositions for forming and detecting plaques|
Provided herein are methods and compositions for the in vitro formation of an array of plaque particles for use in biological assays, diagnosis, drug discovery and drug development. More specifically, the embodiments described herein relate to the in vitro synthesis of plaque particles when treated with biofluids and identification of such plaque particles by a variety of detection systems.
|Optical capsule and spectroscopic method for treating and diagnosing the intestinal tract|
A device and method for mapping, diagnosing and treating disorders or other diseases, disorders or conditions (e.g., bleeding, ischemic or necrotic tissue, and presence of certain chemicals or substances) of the intestinal tract is provided using a capsule passing through the intestinal tract and sensing optical characteristics as the capsule passes through. Further, a capsule tracking system is provided for tracking a capsule's location along the length of an intestinal tract as various treatment and/or sensing modalities are employed.
|Methods and pomegranate extract composition for treating diabetes related atherosclerotic complications in humans|
One or more embodiments of the invention are directed to methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans. The methods comprise the step of administering to the patients a composition comprising a therapeutically effective amount of an extract from pomegranate..
|Method for detection of characteristics of organ fibrosis|
The disclosed invention is a method for detecting indications of the presence of liver disease and other fibrotic diseases using a magnetic-resonance based technique for measuring fine tissue and bone textures. Specifically, the invention focuses on adaptations to this prior art to facilitate assessment of the presence and severity of liver disease, lung disease, and other fibrotic disease by measuring spatial wavelengths characteristic of the specific disease process across an areal cross-section through an organ.
|Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases|
The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a pde-4 inhibitor, a pde-5 inhibitor, a compound that elevates cgmp and/or pkg, a stimulator of guanylyl cyclase and/or pkg, a combination of a compound that elevates cgmp, pkg or no with an antioxidant that decreases ros, or a compound that increases mmp activity..
|Antagonists of cb1 receptor|
The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
|5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienyl)ethyl]] amino-1-naphthol, and preparing method and use thereof|
The present disclosure relates to 5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienypethyl]]amino-1-naphthol, a method for preparing the same, and use of 5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienypethyl]]amino-1-naphthol as a reference compound for determining an impurity in rotigotine or a preparation thereof.. .
|Device and method for tacking plaque to blood vessel wall|
A tack device for holding plaque against blood vessel walls in treating atherosclerotic occlusive disease can be formed as a thin, annular band of durable, flexible material. The tack device may also have a plurality of barbs or anchoring points on its outer annular periphery.
|Methods for treatment of nephrotic syndrome and related conditions|
The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein.
|Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease|
Novel isoforms of apolipoprotein c-i (apoc-i), namely apolipoprotein c-i1 (apoc-i1) and apolipoprotein c-i1′ (apoc-i1′), both of which have a molecular weight of approximately 90 daltons greater than native apolipoprotein c-i (seq id no:6) and native apolipoprotein c-i′ (seq id no:7), are shown to be both biomarkers for diagnosing atherosclerotic disease as well as risk factors for subjects having increased risk of developing an atherosclerotic disease.. .
|Modulation of angiopoietin-like 3 expression|
Provided herein are methods, compounds, and compositions for reducing expression of an angptl3 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal.
|Anti-pdgfr-beta antibodies and uses thereof|
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
|Method and system for determining whether arterial tissue comprises atherosclerotic plaque|
Provided herein are methods and systems to determine at least one mechanical property of a tissue sample and, based upon the determined at least one mechanical property, whether the tissue sample comprises atherosclerotic plaque. The method comprises generating a shear wave in an arterial tissue sample by applying an acoustic impulse thereto; measuring propagation of the shear wave via an optical coherence elastography apparatus; determining at least one mechanical property of the arterial tissue sample based on the propagation of the shear wave; and comparing the at least one mechanical property of the arterial tissue sample to a reference data set to determine whether the arterial tissue sample comprises atherosclerotic plaque.
|Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases|
Described herein are compounds of formula (i), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.. .
|Combination therapy in treatment of oncological and fibrotic diseases|
The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (vegfrs) in conjunction with a thrombin inhibitor.. .
|Method for diagnosing whether a subject is at high risk for developing atherosclerotic vascular disease|
A method for diagnosing whether a subject is at high risk for developing atherosclerotic vascular disease (asvd) is provided. The method comprises the following steps: (1) providing a specimen from a subject; (2) analyzing the specimen by using a gradient gel electrophoresis analysis; and (3) based on the result of the gel electrophoresis analysis in step (2), determining if the subject is at high risk for developing atherosclerotic vascular disease..
|Electrostimulation in treating cerebrovascular conditions|
A system for treating a medical condition in a living body, comprising two subsystems, an implant subsystem and an electrical stimulation unit subsystem. The implant subsystem comprises at least one electrostimulation module, contains at least one electrically conductive electrode and, preferably, an anchoring member.
|Tuned rf energy and electrical tissue characterization for selective treatment of target tissues|
A catheter and catheter system can use energy tailored for remodeling and/or removal of target material along a body lumen, often of atherosclerotic material of a blood vessel of a patient. An elongate flexible catheter body with a radially expandable structure may have a plurality of electrodes or other electrosurgical energy delivery surfaces to radially engage atherosclerotic material when the structure expands.
Popular terms: [SEARCH]
Follow us on Twitter
This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.